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Abstract
Objective—This study examines the hypothesis that chronic inflammation is associated with a
higher risk of cardiac death compared to the risk of non-fatal myocardial infarction.
Methods—Cardiac death and non-fatal MI events were identified in the ARIC cohort during
follow-up from 1987 through 2001. Markers of inflammation and hemostasis were determined at
baseline using standardized procedures. Cox proportional hazard regression and polytomous
logistic regression were used to estimate associations.
Results—We observed a positive gradient in incidence of sudden cardiac death, non-sudden
cardiac death and non-fatal MI in association with decreasing levels of albumin and increasing
levels of white blood cell count and of markers of hemostasis (fibrinogen, von Willebrand factor,
factor VIIIc). Associations for von Willebrand factor (vWF) and factor VIIIc were stronger for
fatal relative to non-fatal events (3rd versus 1st tertile hazard ratios: vWF: SCD 2.67 (95% CI 1.80,
3.96), NSCD 2.11 (95% CI 1.40, 3.19), non-fatal MI 1.40 (95% CI 1.17, 1.67); factor VIIIc: SCD
2.58 (95% CI 1.77, 3.78), NSCD 2.01 (95% CI 1.38, 2.93), non-fatal MI 1.48 (95% CI 1.24, 1.78).
Gradients of association for fibrinogen and white blood cell count, examined over tertiles of
distribution and per one SD increase, were similar for the three endpoints. All associations were
independent of smoking status.
Conclusion—Von Willebrand factor and factor VIIIc are associated with an increased risk of
cardiac death as compared to the risk of non-fatal MI.
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Inflammation and hemostasis play a central role in the development and progression of
atherosclerotic lesions [1-3]. Chronic inflammation, associated with conditions such as
smoking, diabetes, hypertension, and obesity, promotes expression of pro-inflammatory
cytokines, attracting leukocytes and monocytes to the developing plaque [4]. Systemic
markers of inflammation are associated positively with risk of cardiovascular events in both
cross-sectional and prospective studies [5-11]. Likewise, increased levels of circulating
markers of hemostasis are associated with increased risk of secondary cardiovascular events
and to a lesser extent, increased risk of primary events [5,8,12].
Few prospective studies have explored differences in the association of markers of
inflammation and hemostasis with different coronary heart disease outcomes. In this study,
we used data from the Atherosclerosis Risk in Communities (ARIC) cohort to examine the
association of the following selected markers of inflammation and hemostasis: white blood
cell count, serum albumin, plasma fibrinogen, von Willebrand factor and Factor VIIIc, with




The ARIC cohort is a biracial cohort, consisting of 15,792 men and women, 45-64 years of
age at baseline (1987-1989), selected as probability samples from four US communities
located in North Carolina, Mississippi, Minnesota, and Maryland [13]. Follow-up of the
ARIC cohort members is conducted annually through telephone interviews. In addition,
three triennial follow up visits were conducted after the baseline data collection.
The present study is based on data obtained at baseline (1987-1989) and during follow-up
through December 31, 2001. We eliminated from analysis (exclusions not mutually
exclusive) persons who did not report a black or white race on their baseline questionnaire
(n=48), the small number of persons who were black and residing in the Minnesota or
Maryland communities (n=55), persons missing outcome information (n=9), persons with
coronary heart disease identified at baseline (n= 766) or those missing baseline CHD
information (n=344), as well as persons missing baseline information on the following
exposures and selected analysis covariates: fibrinogen (n=276), von Willebrand factor
(n=273), factor VIIIc (n=281), white blood cell count (n=246), albumin (n=150), systolic
blood pressure (n=14), anti-hypertension medication (n=8), cigarette smoking status (n=11),
cigarette years of smoking (n=279), and HDL-cholesterol (n=249). The final analysis cohort
consisted of 13,975 ARIC cohort members.
Baseline measurements
Physical examination of the cohort members and assessment of their risk factor was
conducted during the baseline visit. Members of the ARIC cohort had blood drawn from an
antecubital vein into tubes containing EDTA (lipids), sodium citrate (hemostatic assays), or
a separating gel (glucose and albumin). Plasma HDL-cholesterol levels were measured using
the method of Warnick et al [14]. Plasma total cholesterol levels were determined
enzymatically [15] using a Cobas-Bio analyzer with reagents purchased from Boehringer
Mannheim Biochemicals, Indianapolis, IN. White blood cell count was determined in the
whole blood sample using a Coulter Counter. Plasma levels of fibrinogen, von Willebrand
factor and factor VIIIc were determined in the ARIC Central Hemostasis Laboratory using
established procedures [16]. Plasma fibrinogen levels were determined using the thrombin
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time titration method, with reagents obtained from General Diagnostics Organon Technica
Co., Morris Plains, NJ. Von Willebrand factor antigen was determined using ELISA kits
from American Bioproducts Co. Factor VIII activity was determined on the basis of a
coagulation titration curve established using factor VIII–deficient plasma (George King
Biochemical Inc., Overland Park, KS). Reliability coefficients for measurement of the
hemostatic factors in a sample of ARIC study participants conducted over several weeks
were 0.68 for von Willebrand factor, 0.86 for Factor VIIIc, and 0.72 for fibrinogen [10,16].
Body mass index was calculated as the ratio of weight in kilograms to height in meters
squared. Sitting blood pressure was measured three times using a random zero
sphygmomanometer. Blood pressure calculations were made as an average of the second
and third measurement. Hypertension was defined as present, based on use of
antihypertensive medication within two weeks of baseline data collection, or systolic blood
pressure greater than or equal to 140 mm Hg or diastolic blood pressure greater than or
equal to 90 mm Hg. Baseline diabetes was defined as either a self-reported physician’s
diagnosis of diabetes, use of hypoglycemic medications, non-fasting serum glucose levels
greater than or equal to 11.1 mmol/L, or fasting (≥ 8 hr) serum glucose level greater than or
equal to 7.0 mmol/L.
Highest attained level of education was defined on the basis of a personal report at baseline
of the highest grade completed in school and categorized as low (11th grade or less) or high
(12th grade and above).
Outcome ascertainment
Incident sudden cardiac death cases—All deaths attributed to coronary heart disease
in the main ARIC adjudication were reviewed to ascertain whether each event was due to
sudden cardiac death. These cases underwent a separate physician panel review using a
uniform abstraction form to determine whether the death was characterized as a sudden,
pulseless condition without a known non-cardiac cause. Adjudication was performed
independently by two physicians on the basis of data obtained from death certificates,
informant interviews, physician questionnaires, coroner reports, or hospital discharge
summaries. This review was performed for both in- and out-of-hospital deaths. Inter-
reviewer reliability was evaluated in a subset of cases. The kappa coefficient describing the
classification of sudden cardiac death between the two physician reviewers was 0.79. Initial
discordant classification was resolved by a third independent review.
Incident non-sudden cardiac death
Incident non-sudden cardiac death cases, identified during follow-up, were defined as those
cases of death meeting ARIC study criteria for definite fatal myocardial infarction or
definite or possible fatal coronary heart disease [13], which did not meet sudden cardiac
death criteria.
Incident non-fatal myocardial infarction—Incident non-fatal myocardial infarction,
defined by the ARIC study criteria [13] , was identified during follow-up through annual
questionnaires, review of medical discharge records (presence of chest pain, cardiac
biomarkers, electrocardiograms), or at follow-up examinations [13,17].
Statistical analysis
Age-adjusted incidence rates were calculated per tertiles of distribution of von Willebrand
factor, Factor VIIIc, fibrinogen, albumin, and white blood cell count. Regression analysis
was performed using Cox proportional hazard models of the association of marker tertiles
with the hazard of sudden cardiac death, non-sudden cardiac death, or non-fatal MI. The
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following baseline variables: age, race/ARIC center, body mass index, gender, diabetes,
cigarette years of smoking, cigarette smoking status, systolic blood pressure, use of anti-
hypertensive medication, total cholesterol and HDL-cholesterol were evaluated for inclusion
into regression models on the basis of existing literature and retained according to a 10%
change-in-estimate criterion [18]. The race/ARIC center variable was created as a
categorical variable encompassing five categories of race and ARIC center. Potential
interaction terms were evaluated using partial likelihood ratio tests based on nested models.
All continuous variables were evaluated for linearity of association with the main outcome.
The Cox proportional hazard assumption was examined for all variables individually and for
the final model using the Cox test and on the basis of ln-ln plots and plots of scaled
Schoenfeld residuals. Nominal polytomous logistic regression analysis was used to address
the question of competing risk of cardiac death in the analysis of the risk of non-fatal MI.
All analyses were performed using STATA 10.0 (STATA Corp., College Station, TX).
RESULTS
Cohort participants, whose levels of von Willebrand factor, factor VIIIc, fibrinogen and
white blood cell count were in the highest tertiles of distribution, and whose albumin levels
were in the lowest tertile of the distribution, shared the following characteristics. They were
on average older, had higher BMI values, and had higher baseline glucose levels than those
cohort participants whose levels of the markers of inflammation and hemostasis were in the
lowest (highest for albumin) tertile of distribution (Table 1). Prevalence of ever smoking and
of diabetes and hypertension was higher among those with highest, as compared to the
lowest, levels of von Willebrand factor, factor VIIIc, fibrinogen and white blood cell count,
and lowest levels of albumin. Those differences were statistically significant at p=0.05.
The age-adjusted rate of incidence of non-fatal MI (NFMI) was consistently higher than that
of sudden (SCD) or non-sudden (NSCD) cardiac death overall and across all exposures
(overall incidence rates (IR) per 10,000 person-years : IRSCD = 11.7 (95% CI 10.2, 13.4),
IRNSCD = 9.8 (95% CI 8.5, 11.4), and IRNFMI= 42.5 (95% CI 39.5, 45.7)). The age-adjusted
incidence rates for sudden and non-sudden cardiac death were similar in magnitude across
all exposure categories (Table 2). Incidence of sudden cardiac death, non-sudden cardiac
death and non-fatal MI increased across increasing tertiles of von Willebrand factor, factor
VIIIc, fibrinogen and white blood cell count and across decreasing tertiles of serum albumin,
with a greater difference in incidence rates between the second and third tertile, as compared
to the first and second tertile for all exposures except albumin.
In analyses stratified by gender, men had significantly higher crude rates of incidence of
sudden cardiac death and non-fatal MI than women, overall and for all exposure categories.
There were no significant gender-differences in rates of non-sudden cardiac death, either
overall or across exposure categories. For all exposures examined, the rates of sudden
cardiac death and non-sudden cardiac death were higher among blacks, as compared to
whites. There were no significant race differences in the rates of non-fatal MI overall and
across exposure categories (race and gender stratified data not shown).
We examined the association of the selected markers of hemostasis and inflammation with
the risk of non-fatal MI, sudden cardiac death, and non-sudden cardiac death in tertiles of
marker distribution using Cox proportional hazard regression models adjusted for the
following covariates: age, gender, race ARIC center, cigarette years of smoking, and
cigarette smoking status. The hazard ratios for sudden cardiac death, non-sudden cardiac
death, and nonfatal MI increased across exposure levels for all exposure categories (Table
3). All hemostatic (von Willebrand factor, Factor VIIIc, fibrinogen) and inflammatory
(white blood cell count, albumin) markers examined were associated strongly with the risk
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of sudden cardiac death and of non-sudden cardiac death. With respect to non-fatal MI, we
observed modest associations for von Willebrand factor, factor VIIIc, and white blood cell
count, a strong association for fibrinogen, and no association for albumin. Adjustment for
the following covariates associated with CHD outcomes: diabetes, total cholesterol, HDL-
cholesterol, systolic blood pressure, and use of anti-hypertensive medication, in addition to
the demographic variables and smoking, did not alter estimates for the risk of sudden cardiac
death, but decreased the estimates for the associations of the highest, as compared to the
lowest tertiles, of factor VIIIc and fibrinogen with the risk of non-sudden cardiac death to
statistically non-significant levels (HRfactor VIII=1.43 (95% CI 0.97, 2.11, HRfibrinogen= 1.44
(95% CI 0.96, 2.17)). The estimate for the association of factor VIIIc with the risk of non-
fatal MI was likewise decreased with full adjustment to a statistically non-significant level
(HR= 1.18 (95% CI 0.98, 1.42)). The hazard ratio of the association of the highest, as
compared to the lowest, tertile of factor VIIIc with the risk of sudden cardiac death remained
statistically significant after adjustment (HR=2.09 (95% CI 1.42, 3.08)).
Likelihood ratio tests of nested models with and without gender and race interaction terms,
as well as analyses of joint and independent effects, suggested that neither race nor gender
modified the association of albumin, white blood cell count, fibrinogen, von Willebrand
factor, and factor VIIIc with the risk of sudden cardiac death, or non-sudden cardiac death,
or non-fatal MI.
Sensitivity analyses
Since cigarette smoking contributes significantly to the level of chronic systemic
inflammation, we examined the associations of the selected markers of inflammation and
hemostasis with the risk of cardiac death and non-fatal MI among never smokers and among
ever-smokers. We did not observe a significant difference in the point estimates among
never-smokers as compared to the total sample population, suggesting a negligible effect
modification by smoking of the association of the selected markers of inflammation and
hemostasis with sudden or non-sudden cardiac death, or non-fatal MI (Figure 1). Likelihood
ratio tests of the interaction of smoking status with all exposures were non-significant for all
outcomes. Model 2 shown in Table 3, represents association of tertiles of the selected
markers with the risk of CHD outcomes adjusted for the demographic covariates and for
smoking. Incorporation of baseline diabetes, a condition associated with chronic
inflammatory states and advanced atherosclerosis, into this model only slightly attenuated
the estimates of the hazard ratios for sudden cardiac death, non-sudden cardiac death and
non-fatal MI in association with all selected exposures, except for albumin. Diabetes
attenuated the estimate of the association of the lowest tertile of albumin with the risk of
non-fatal MI to a statistically non-significant level (hazard ratio 1.20 (95% CI 0.99, 1.44))
Inclusion of education, or of median household income, as covariates in the Cox regression
models, did not alter the estimates of risk associated with any of the exposures.
Baseline hemostatic and inflammatory factors were also associated with non-cardiac
mortality, although the relative strength of the association was lower than for cardiac death.
Hazard ratios of non-cardiac death, adjusted for age, gender, race, ARIC center, and
smoking, for the highest versus the lowest tertiles of von Willebrand factor and factor VIIIc
with the risk of non-cardiac death were 1.55 (95% CI 1.34, 1.78) and 1.63 (95% CI 1.42,
1.88) respectively.
We performed polytomous logistic regression to confirm, or refute, observations obtained
with single endpoint models (Table 4). Regression was performed with coronary heart
disease events categorized as follows: non-fatal MI not followed by cardiac death, sudden
cardiac death not preceded by a non-fatal MI, non-sudden cardiac death not preceded by a
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non-fatal MI, sudden cardiac death following a non-fatal MI, or non-sudden cardiac death
following a non-fatal MI. There were 21 cases of sudden cardiac death and 46 cases of non-
sudden cardiac death which were preceded by a non-fatal MI. Those numbers are too small
for a meaningful analysis of effects stratified by exposure categories. We therefore, focused
analysis on the three independent outcomes: sudden and non-sudden cardiac deaths and non-
fatal MI. Results of this multinomial analysis, presented in Table 4, confirmed results from
individual analyses suggesting a stronger association of von Willebrand factor and factor
VIII with the risk of sudden and non-sudden cardiac death as compared to the risk of non-
fatal MI. A formal test of the null hypothesis that the strength of the association is the same
for the three outcomes, indicated a significant difference in the association of von
Willebrand factor with sudden (p<0.01) and non-sudden (p<0.01) cardiac death as compared
to non-fatal MI and a significant difference in the association of factor VIIIc with sudden
(p<0.01) and non-sudden (p<0.01) cardiac death as compared to non-fatal MI.
DISCUSSION
In this study, we observed a positive association of high white blood cell count, fibrinogen,
von Willebrand factor, and of factor VIIIc and a negative association of high albumin with
increased incidence of fatal and non-fatal coronary heart disease events during an average
12.4 years of follow up. Our results corroborate observations from published studies
[5,19-24] extending previously reported ARIC study results [5,22] to a longer follow up
time and providing a comparative analysis of the association of those markers with different
CHD outcomes. Presented data suggest a stronger association of factor VIII and von
Willebrand factor with risk of cardiac death (sudden and non-sudden), as compared to the
risk of non-fatal MI.
Coagulation factor VIII, secreted by the liver, and to a lesser extent by the spleen and cells
of the lymphatic system, exists in the circulation in the form of a stable complex with von
Willebrand factor [25,26], a multimeric glycoprotein produced primarily by the endothelium
in response to injury and inflammatory stimuli [24]. This results in von Willebrand factor
and factor VIIIc being highly correlated and showing almost identical associations with
coronary heart disease. Binding of von Willebrand factor to the subendothelial matrix and to
activated platelets, facilitates platelet accumulation at the site of injury and leads to eventual
formation of a thrombus plug [27,28]. Elevated plasma levels of von Willebrand factor
reflect presence of endothelial injury and dysfunction in a manner more specific than that of
the other inflammatory and hemostatic markers [29]. In this study, we found that plasma
levels of factor VIIIc and von Willebrand factor, although positively associated with all
CHD outcomes, were more strongly associated with cardiac death (sudden and non-sudden)
as compared to non-fatal MI. Those results would suggest, indirectly, a specific role of
endothelial dysfunction in fatal CHD events [30,31].
Our finding that smoking does not modify the association of von Willebrand factor, factor
VIII, fibrinogen, and white blood cell count with coronary heart diseases events, confirms
and extends the data of Lee et al. [19] in which the authors observed that the associations of
white blood cell count with cardiovascular mortality and with the incidence of coronary
heart disease were independent of smoking status.
We observed an inverse association of albumin with cardiac death, but we did not observe
an independent association of albumin with incidence of non-fatal MI. These data are in
agreement with the report by Kuller et al. [20], suggesting a stronger association of albumin
with fatal, as compared to non-fatal CHD events.
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Other studies of the association of inflammatory and hemostatic markers with fatal and non-
fatal events have not been conclusive. Investigators of the Northwick Park Heart Study, in
long-term follow up of persons without prior myocardial infarction [32,33], observed an
association of factor VII activity with fatal ischemic heart disease events, but not with non-
fatal events. Those results have not been reproduced by other studies [6,34,35].
There were several limitations to this study. The study lacked extensive information (e.g. C-
reactive protein) concerning baseline inflammatory status. We examined only baseline
exposure status; it was beyond the scope of this study to examine the effect of change in
levels of inflammatory and hemostatic markers over the period of follow-up.
The strength of this study lies in its prospective design. We have observed an association of
markers of inflammation and hemostasis obtained from blood samples collected at baseline
with coronary heart disease events occurring during an extensive (12.4 year) follow up
period. The fact that these associations were present for different markers argues against
them resulting from chance and is consistent with the presence of a sustained chronic
inflammatory burden, which then impacts cardiovascular events. The definition of sudden
cardiac death used in this study was constructed to best capture those cases of cardiac death
that were truly sudden and unexpected and combined all available cardiac death information.
In conclusion, our observations add to the existing hypotheses concerning different roles that
inflammatory and hemostatic processes may play in the development of fatal and non-fatal
coronary heart disease outcomes [34,36]. Furthermore, our results suggest that elevated
plasma levels of factor VIIIc and von Willebrand factor may aid in identifying those at
increased risk of sudden cardiac death. Cardiac death, particularly sudden cardiac death [37],
is often the first manifestation of underlying pathology, yet traditional risk factors do not
specifically identify those at increased risk [38-40]. Observations presented here may help
clarify the role of inflammation and impairment of hemostasis in the pathology of sudden
cardiac death and aid in identifying persons at increased risk and perhaps serve as guidelines
for thrombolytic therapy.
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Association of markers of inflammation and hemostasis with the risk of sudden cardiac
death, non-sudden cardiac death, and non-fatal MI in the total sample population (A.) and
among never smokers (B.). Hazard ratio per one SD difference in exposure. Analysis
adjusted for age, gender, race, ARIC center, cigarette years of smoking (total sample only),
and cigarette smoking status (total sample only). vwF: von Willebrand factor; WBC: white
blood cell count ● sudden cardiac death; ■ non-sudden cardiac death; ▲ non-fatal MI
Kucharska-Newton et al. Page 10














Kaplan-Meier curves of cumulative survival according to tertiles of von Willebrand factor,
Factor VIIIc, fibrinogen, white blood cell count, and albumin. Data adjusted for age and
presented for the following outcomes: non-data MI, non-sudden cardiac death, and sudden
cardiac death. The ARIC study cohort 1987-2001.  1st tertile ;  2nd tertile;
 3rd tertile
Kucharska-Newton et al. Page 11
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Table 4
Tertiles of markers of inflammation and hemostasis and the relative risk of sudden cardiac death, non-sudden
cardiac death, and non-fatal MI. Odds ratio estimates determined by polytomous logistic regression with no
events as the base category. Data presented for independent outcomes only. Analysis adjusted for age, gender,









Von Willebrand factor (%)
 <92 1.00 1.00 1.00
 92-129 1.30 (0.82, 2.06) 1.56 (0.91, 2.67) 1.01 (0.82, 1.21)
 >129 2.58 (1.71, 3.90) 2.55 (1.55, 4.21) 1.37 (1.13, 1.66)
Factor VIIIc (%)
 <112 1.00 1.00 1.00
 112-141 1.35 (0.86, 2.12) 0.56 (0.32, 0.97) 0.98 (0.81, 1.20)
 >141 2.47 (1.64, 3.71) 1.83 (1.19, 2.80) 1.31 (1.08, 1.60)
Fibrinogen (μmol/L)
 <7.97 1.00 1.00 1.00
 7.97-9.41 0.96 (0.61, 1.52) 0.96 (0.59, 1.57) 1.57 (1.27, 1.95)
 >9.41 2.25 (1.52, 3.32) 1.46 (0.93, 2.28) 1.91 (1.55, 2.36)
WBC (x10−6)
 ≤5.1 1.00 1.00 1.00
 5.1-6.1 0.90 (0.56, 1.42) 1.72 (0.97, 3.03) 1.21 (0.96, 1.53)
 ≥6.1 1.84 (1.28, 2.63) 2.84 (1.73, 4.65) 1.50 (1.22, 1.85)
Albumin (g/L)
 <38 1.70 (1.12, 2.58) 1.89 (1.14, 3.15) 1.01 (0.83, 1.23)
 38-40 1.31 (0.82, 2.09) 1.32 (0.74, 2.35) 1.01 (0.82, 1.26)
 >40 1.00 1.00 1.00
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